Peptide Comparison
ARA-290 vs Klow
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
ARA-290 has stronger documented evidence (Phase 2) than Klow (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. Klow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| ARA-290 | Klow | |
|---|---|---|
| Class | EPO-derived peptide; innate repair receptor (IRR) agonist | Four-component regenerative blend (Glow + KPV anti-inflammatory) |
| Drug class | Tissue Repair | Tissue Repair |
| Mechanism | Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect | Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. |
| Route | SC injection | SC injection |
| Half-life | ~2 hrs | Composite: hours to days per component (TB-500 longest) |
| Dosage (research) | 2-4 mg SC daily for 28 days (trial protocol) | Typical SC protocols deliver ~250 mcg of each component daily (per-component basis from a combined-mg vial) for 4-8 week loading cycles. Confirm vial composition with vendor before computing per-component dose |
| Evidence tier | Phase 2 | Anecdotal |
| Research depth | 68 indexed | — |
| Availability | Investigational | Compounding Restricted |
| Reported risks | Injection site reactions; Phase 2/3 data limited | No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick ARA-290 or Klow?
ARA-290 has stronger documented evidence (Phase 2) than Klow (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. Klow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between ARA-290 and Klow?
ARA-290 is classed as EPO-derived peptide; innate repair receptor (IRR) agonist; Klow is classed as Four-component regenerative blend (Glow + KPV anti-inflammatory). Reported mechanism: ARA-290, Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect; Klow, Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. Reported half-life: ARA-290, ~2 hrs; Klow, Composite: hours to days per component (TB-500 longest). Routes in published studies: ARA-290, SC injection; Klow, SC injection.
Which has stronger evidence, ARA-290 or Klow?
ARA-290 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. ARA-290 is graded Phase 2, with 3 cited sources on its reference page and 68 indexed studies. Klow is graded Anecdotal, with 4 cited sources on its reference page.
Which is more accessible, ARA-290 or Klow?
Neither ARA-290 nor Klow is an FDA-approved drug. Catalog status: ARA-290, Investigational; Klow, Compounding Restricted.
Are ARA-290 and Klow ever combined?
ARA-290 and Klow appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…